Moleculin Biotech, Inc.

LSE:0K2H Stock Report

Market Cap: US$7.9m

Moleculin Biotech Valuation

Is 0K2H undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0K2H when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0K2H's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0K2H's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0K2H?

Key metric: As 0K2H is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0K2H. This is calculated by dividing 0K2H's market cap by their current book value.
What is 0K2H's PB Ratio?
PB Ratio1.1x
BookUS$7.48m
Market CapUS$7.86m

Price to Book Ratio vs Peers

How does 0K2H's PB Ratio compare to its peers?

The above table shows the PB ratio for 0K2H vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average5.8x
APTA Aptamer Group
6.5xn/aUK£5.8m
GENF Genflow Biosciences
6.6xn/aUK£5.7m
CIZ Cizzle Biotechnology Holdings
9xn/aUK£7.1m
ROQ Roquefort Therapeutics
1.1xn/aUK£5.4m
0K2H Moleculin Biotech
1.1x-2.3%US$7.9m

Price-To-Book vs Peers: 0K2H is good value based on its Price-To-Book Ratio (1.1x) compared to the peer average (6x).

Price to Book Ratio vs Industry

How does 0K2H's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.50m
VAL ValiRx
0.6xn/aUS$2.81m
No more companies available in this PB range
0K2H 1.1xIndustry Avg. 2.8xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0K2H is good value based on its Price-To-Book Ratio (1.1x) compared to the UK Biotechs industry average (2.8x).

Price to Book Ratio vs Fair Ratio

What is 0K2H's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0K2H PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0K2H's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0K2H forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$18.00
0%
55.6%US$28.00US$8.00n/a2
Nov ’25n/a
US$25.00
0%
20.0%US$30.00US$20.00n/a2
Oct ’25US$2.43
US$25.00
+930.4%
20.0%US$30.00US$20.00n/a2
Sep ’25US$2.48
US$25.00
+907.6%
20.0%US$30.00US$20.00n/a2
Aug ’25US$3.21
US$25.00
+680.0%
20.0%US$30.00US$20.00n/a2
Jul ’25n/a
US$35.00
0%
30.9%US$45.00US$20.00n/a3
Jun ’25US$4.53
US$35.00
+672.6%
30.9%US$45.00US$20.00n/a3
May ’25US$5.15
US$35.00
+579.6%
30.9%US$45.00US$20.00n/a3
Apr ’25US$6.00
US$35.00
+483.3%
30.9%US$45.00US$20.00n/a3
Mar ’25n/a
US$110.00
0%
83.6%US$240.00US$45.00n/a3
Feb ’25US$7.65
US$110.00
+1,337.9%
83.6%US$240.00US$45.00n/a3
Jan ’25US$11.94
US$110.00
+821.6%
83.6%US$240.00US$45.00n/a3
Dec ’24US$9.10
US$142.50
+1,465.1%
68.4%US$240.00US$45.00n/a2
Nov ’24US$6.91
US$120.00
+1,635.4%
71.4%US$240.00US$45.00n/a3
Oct ’24US$5.92
US$120.00
+1,925.3%
71.4%US$240.00US$45.00US$2.433
Sep ’24US$8.44
US$120.00
+1,322.2%
71.4%US$240.00US$45.00US$2.483
Aug ’24US$10.05
US$130.00
+1,193.5%
59.8%US$240.00US$75.00US$3.213
Jul ’24n/a
US$130.00
0%
59.8%US$240.00US$75.00n/a3
Jun ’24n/a
US$130.00
0%
59.8%US$240.00US$75.00US$4.533
May ’24US$10.65
US$130.00
+1,120.7%
59.8%US$240.00US$75.00US$5.153
Apr ’24US$13.49
US$130.00
+863.7%
59.8%US$240.00US$75.00US$6.003
Mar ’24US$18.33
US$130.00
+609.2%
59.8%US$240.00US$75.00n/a3
Feb ’24n/a
US$130.00
0%
59.8%US$240.00US$75.00US$7.653
Jan ’24US$17.09
US$130.00
+660.7%
59.8%US$240.00US$75.00US$11.943
Dec ’23US$21.49
US$130.00
+504.9%
59.8%US$240.00US$75.00US$9.103
Nov ’23US$15.15
US$175.00
+1,055.1%
41.0%US$240.00US$75.00US$6.913

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Formycon

€844.9m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.65

7D

3.6%

1Y

-24.5%

hVIVO

UK£134.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.21

7D

-3.8%

1Y

4.9%

Regeneron Pharmaceuticals

US$81.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$754.96

7D

2.0%

1Y

-7.1%